Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury

Free Radical Biology and Medicine

Volumn 50, Issue 1, 2011, Pages 179-195

  Mukhopadhyay, Partha ^a   Horváth, Bela ^a,e   Rajesh, Mohanraj ^a   Matsumoto, Shingo ^b   Saito, Keita ^b   Bátkai, Sándor ^a   Patel, Vivek ^a   Tanchian, Galin ^a   Gao, Rachel Y ^a   Cravatt, Benjamin F ^c   Haskó, György ^d   Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cannabinoid receptors; Cardiomyopathy; Cell death; Endocannabinoids; Free radicals; Nitrosative stress; Oxidative stress

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 3 NITROTYROSINE; 4 HYDROXYNONENAL; ANANDAMIDE; CYTOCHROME C; DOXORUBICIN; FATTY ACID AMIDASE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOMYOPATHY; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; GENE DELETION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HUMAN; HUMAN CELL; MALE; MOUSE; NEUTROPHIL; NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

AMIDOHYDROLASES; ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; CELLS, CULTURED; DOXORUBICIN; ENDOCANNABINOIDS; HEART; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB1;

MUS;

EID: 78650716667     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.11.002     Document Type: Article

References (75)

1. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202
2. P. Pacher, S. Batkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 58 2006 389 462
3. P. Pacher, and S. Steffens The emerging role of the endocannabinoid system in cardiovascular disease Semin. Immunopathol. 31 2009 63 77
4. P. Pacher, P. Mukhopadhyay, R. Mohanraj, G. Godlewski, S. Batkai, and G. Kunos Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations Hypertension 52 2008 601 607
5. S. Batkai, and P. Pacher Endocannabinoids and cardiac contractile function: pathophysiological implications Pharmacol. Res. 60 2009 99 106
6. M. Rajesh, B. Mukhopadhyay, G. Hasko, L. Liaudet, K. Mackie, and M. Pacher Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells Br. J. Pharmacol. 160 2010 688 700
7. P. Mukhopadhyay, M. Rajesh, S. Batkai, V. Patel, Y. Kashiwaya, L. Liaudet, O.V. Evgenov, K. Mackie, G. Hasko, and P. Pacher CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes Cardiovasc. Res. 85 2010 773 784
8. K.H. Han, S. Lim, J. Ryu, C.W. Lee, Y. Kim, J.H. Kang, S.S. Kang, Y.K. Ahn, C.S. Park, and J.J. Kim CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages Cardiovasc. Res. 84 2009 378 386
9. F. Dol-Gleizes, R. Paumelle, V. Visentin, A.M. Mares, P. Desitter, N. Hennuyer, A. Gilde, B. Staels, P. Schaeffer, and F. Bono Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice Arterioscler. Thromb. Vasc. Biol. 29 2009 12 18
10. K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, K. Miyata, M. Nakayama, K. Kaikita, T. Obata, M. Takeya, and H. Ogawa Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages Circulation 119 2009 28 36
11. M. Rajesh, P. Mukhopadhyay, G. Hasko, and P. Pacher Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation Biochem. Biophys. Res. Commun. 377 2008 1248 1252
12. F. Montecucco, S. Lenglet, V. Braunersreuther, F. Burger, G. Pelli, M. Bertolotto, F. Mach, and S. Steffens CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion J. Mol. Cell. Cardiol. 46 2009 612 620
13. S. Batkai, D. Osei-Hyiaman, H. Pan, O. El-Assal, M. Rajesh, P. Mukhopadhyay, F. Hong, J. Harvey-White, A. Jafri, G. Hasko, J.W. Huffman, B. Gao, G. Kunos, and P. Pacher Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury FASEB J. 21 2007 1788 1800
14. P. Mukhopadhyay, M. Rajesh, H. Pan, V. Patel, B. Mukhopadhyay, S. Batkai, B. Gao, G. Hasko, and P. Pacher Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy Free Radic. Biol. Med. 48 2010 457 467
15. V. Di Marzo, M. Cote, I. Matias, I. Lemieux, B.J. Arsenault, A. Cartier, F. Piscitelli, S. Petrosino, N. Almeras, and J.P. Despres Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors Diabetologia 52 2009 213 217
16. P. Pacher Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler. Thromb. Vasc. Biol. 29 2009 7 9
17. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
18. K. Ahn, M.K. McKinney, and B.F. Cravatt Enzymatic pathways that regulate endocannabinoid signaling in the nervous system Chem. Rev. 108 2008 1687 1707
19. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, and A.H. Lichtman Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl Acad. Sci. USA 98 2001 9371 9376
20. B.F. Cravatt, A. Saghatelian, E.G. Hawkins, A.B. Clement, M.H. Bracey, and A.H. Lichtman Functional disassociation of the central and peripheral fatty acid amide signaling systems Proc. Natl Acad. Sci. USA 101 2004 10821 10826
21. S.V. Siegmund, E. Seki, Y. Osawa, H. Uchinami, B.F. Cravatt, and R.F. Schwabe Fatty acid amide hydrolase determines anandamide-induced cell death in the liver J. Biol. Chem. 281 2006 10431 10438
22. S. Kotamraju, E.A. Konorev, J. Joseph, and B. Kalyanaraman Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: role of reactive oxygen and nitrogen species J. Biol. Chem. 275 2000 33585 33592
23. 2- and p53-dependent pathways J. Biol. Chem. 279 2004 25535 25543
24. D.M. Weinstein, M.J. Mihm, and J.A. Bauer Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice J. Pharmacol. Exp. Ther. 294 2000 396 401
25. P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro Am. J. Physiol. Heart Circ. Physiol. 296 2009 H1466 H1483
26. P. Pacher, L. Liaudet, P. Bai, L. Virag, J.G. Mabley, G. Hasko, and C. Szabo Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure J. Pharmacol. Exp. Ther. 300 2002 862 867 (Pubitemid 34164989)
27. P. Pacher, L. Liaudet, P. Bai, J.G. Mabley, P.M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M.S. Wolin, J.T. Groves, and C. Szabo Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction Circulation 107 2003 896 904
28. P. Mukhopadhyay, S. Batkai, M. Rajesh, N. Czifra, J. Harvey-White, G. Hasko, Z. Zsengeller, N.P. Gerard, L. Liaudet, G. Kunos, and P. Pacher Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity J. Am. Coll. Cardiol. 50 2007 528 536
29. K. Chandran, D. Aggarwal, R.Q. Migrino, J. Joseph, D. McAllister, E.A. Konorev, W.E. Antholine, J. Zielonka, S. Srinivasan, N.G. Avadhani, and B. Kalyanaraman Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q Biophys. J. 96 2009 1388 1398
30. J.H. Doroshow, and K.J. Davies Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical J. Biol. Chem. 261 1986 3068 3074
31. P. Pacher, S. Batkai, D. Osei-Hyiaman, L. Offertaler, J. Liu, J. Harvey-White, A. Brassai, Z. Jarai, B.F. Cravatt, and G. Kunos Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase Am. J. Physiol. Heart Circ. Physiol. 289 2005 H533 H541
32. P. Pacher, T. Nagayama, P. Mukhopadhyay, S. Batkai, and D.A. Kass Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats Nat. Protoc. 3 2008 1422 1434
33. H.J. Forman Reactive oxygen species and alpha, beta-unsaturated aldehydes as second messengers in signal transduction Ann. NY Acad. Sci. 1203 2010 35 44
34. H.J. Forman, and D.A. Dickinson Introduction to serial reviews on 4-hydroxy-2-nonenal as a signaling molecule Free Radic. Biol. Med. 37 2004 594 596
35. H.J. Forman, J.M. Fukuto, T. Miller, H. Zhang, A. Rinna, and S. Levy The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal Arch. Biochem. Biophys. 477 2008 183 195
36. R.L. Levine Carbonyl modified proteins in cellular regulation, aging, and disease Free Radic. Biol. Med. 32 2002 790 796
37. J.P. Eiserich, M. Hristova, C.E. Cross, A.D. Jones, B.A. Freeman, B. Halliwell, and A. van der Vliet Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils Nature 391 1998 393 397
38. S. Baldus, J.P. Eiserich, M.L. Brennan, R.M. Jackson, C.B. Alexander, and B.A. Freeman Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases Free Radic. Biol. Med. 33 2002 1010
39. F.J. Schopfer, P.R. Baker, and B.A. Freeman NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem. Sci. 28 2003 646 654
40. R. Radi Nitric oxide, oxidants, and protein tyrosine nitration Proc. Natl Acad. Sci. USA 101 2004 4003 4008
41. S.I. Dikalov, W. Li, P. Mehranpour, S.S. Wang, and A.M. Zafari Production of extracellular superoxide by human lymphoblast cell lines: comparison of electron spin resonance techniques and cytochrome C reduction assay Biochem. Pharmacol. 73 2007 972 980
42. N. Mariappan, C.M. Elks, B. Fink, and J. Francis TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction Free Radic. Biol. Med. 46 2009 462 470
43. G. Rothe, A. Oser, and G. Valet Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes Naturwissenschaften 75 1988 354 355
44. D.T. Fearon, and L.A. Collins Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures J. Immunol. 130 1983 370 375
45. S.J. Vowells, S. Sekhsaria, H.L. Malech, M. Shalit, and T.A. Fleisher Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes J. Immunol. Meth. 178 1995 89 97
46. P. Mukhopadhyay, H. Pan, M. Rajesh, S. Batkai, V. Patel, J. Harvey-White, B. Mukhopadhyay, G. Hasko, B. Gao, K. Mackie, and P. Pacher CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model Br. J. Pharmacol. 160 2010 657 668
47. P. Pacher, S. Batkai, and G. Kunos Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice J. Physiol. 558 2004 647 657
48. M. Gary-Bobo, G. Elachouri, J.F. Gallas, P. Janiak, P. Marini, C. Ravinet-Trillou, M. Chabbert, N. Cruccioli, C. Pfersdorff, C. Roque, M. Arnone, T. Croci, P. Soubrie, F. Oury-Donat, J.P. Maffrand, B. Scatton, F. Lacheretz, G. Le Fur, J.M. Herbert, and M. Bensaid Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats Hepatology 46 2007 122 129
49. P. Pacher, and G. Hasko Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning Br. J. Pharmacol. 153 2008 252 262
50. Y. Kadoi, and F. Goto Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine J. Anesth. 20 2006 284 289
51. A. Villanueva, M.S. Yilmaz, W.R. Millington, R.A. Cutrera, D.G. Stouffer, L.H. Parsons, J.F. Cheer, and C. Feleder Central cannabinoid-1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area Shock 32 2009 614 620
52. A. Schafer, J. Pfrang, J. Neumuller, S. Fiedler, G. Ertl, and J. Bauersachs The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats Br. J. Pharmacol. 154 2008 1047 1054
53. A.M. Malfitano, C. Laezza, S. Pisanti, P. Gazzerro, and M. Bifulco Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells Br. J. Pharmacol. 153 2008 1003 1010
54. C.E. Myers, W.P. McGuire, R.H. Liss, I. Ifrim, K. Grotzinger, and R.C. Young Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response Science 197 1977 165 167
55. J.H. Doroshow, G.Y. Locker, I. Ifrim, and C.E. Myers Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine J. Clin. Invest. 68 1981 1053 1064
56. E.A. Konorev, M.C. Kennedy, and B. Kalyanaraman Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates Arch. Biochem. Biophys. 368 1999 421 428
57. S.V. Kalivendi, E.A. Konorev, S. Cunningham, S.K. Vanamala, E.H. Kaji, J. Joseph, and B. Kalyanaraman Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium Biochem. J. 389 2005 527 539
58. W. Zhu, Y. Zou, R. Aikawa, K. Harada, S. Kudoh, H. Uozumi, D. Hayashi, Y. Gu, T. Yamazaki, R. Nagai, Y. Yazaki, and I. Komuro MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes Circulation 100 1999 2100 2107
59. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy N. Engl. J. Med. 339 1998 900 905
60. 2-isoprostanes and 2-arachidonylglycerol as biomarkers of lipid peroxidation in pigs with hepatic ischemia/reperfusion injury J. Surg. Res. 161 2009 139 145
61. P. Pacher, and B. Gao Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases Am. J. Physiol. Gastrointest. Liver Physiol. 294 2008 G850 G854
62. G.D. Dalton, C.E. Bass, C. Van Horn, and A.C. Howlett Signal transduction via cannabinoid receptors CNS Neurol. Disord. Drug Targets 8 2009 422 431
63. A. Riad, S. Bien, D. Westermann, P.M. Becher, K. Loya, U. Landmesser, H.K. Kroemer, H.P. Schultheiss, and C. Tschope Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice Cancer Res. 69 2009 695 699
64. K.J. Davies, and J.H. Doroshow Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase J. Biol. Chem. 261 1986 3060 3067
65. P. Pacher, J.S. Beckman, and L. Liaudet Nitric oxide and peroxynitrite in health and disease Physiol. Rev. 87 2007 315 424
66. C. Szabo, H. Ischiropoulos, and R. Radi Peroxynitrite: biochemistry, pathophysiology and development of therapeutics Nat. Rev. Drug Discovery 6 2007 662 680
67. S. Levrand, C. Vannay-Bouchiche, B. Pesse, P. Pacher, F. Feihl, B. Waeber, and L. Liaudet Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo Free Radic. Biol. Med. 41 2006 886 895
68. I.G. Obrosova Peroxynitrite and cardiomyocyte cell death: an evolving story. A commentary on "Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo" Free Radic. Biol. Med. 41 2006 866 868
69. A. Denicola, and R. Radi Peroxynitrite and drug-dependent toxicity Toxicology 208 2005 273 288
70. S. Wang, S. Kotamraju, E. Konorev, S. Kalivendi, J. Joseph, and B. Kalyanaraman Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide Biochem. J. 367 2002 729 740
71. P. Pacher, and C. Szabo Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease Am. J. Pathol. 173 2008 2 13
72. J. Liu, B. Gao, F. Mirshahi, A.J. Sanyal, A.D. Khanolkar, A. Makriyannis, and G. Kunos Functional CB1 cannabinoid receptors in human vascular endothelial cells Biochem. J. 346 2000 835 840 (Pubitemid 30171048)
73. A. Santoro, S. Pisanti, C. Grimaldi, A.A. Izzo, F. Borrelli, M.C. Proto, A.M. Malfitano, P. Gazzerro, C. Laezza, and M. Bifulco Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon Int. J. Cancer 125 2009 996 1003
74. G. Kunos, D. Osei-Hyiaman, S. Batkai, K.A. Sharkey, and A. Makriyannis Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol. Sci. 30 2009 1 7
75. Tam, J., Vemuri, V.K., Liu, J., Batkai, S., Mukhopadhyay, B., Godlewski, G., Osei-Hyiaman, D., Ohnuma, S., Ambudkar, S.V., Pickel, J., Makriyannis, A., Kunos, G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 120:2953-2966; 2010.